Q-omics provides the consensus-scored PLA2G5 profile across patient tissues and cancer cell-line models. PLA2G5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PLA2G5 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLA2G5 RNA expression shows 21,812 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where PLA2G5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G5 survival associations across molecular data types. PLA2G5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G5 RNA expression–survival associations across cancer types. High PLA2G5 expression shows unfavorable associations in KIRP, LUSC, BLCA and LGG, but favorable associations in SKCM and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PLA2G5 RNA expression.
This table summarizes PLA2G5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G5 shows lower tumor expression in LUAD, BLCA, UCEC, LUSC and COAD and higher tumor expression in KIRC. The KIRC box plot shows higher PLA2G5 RNA expression in tumor versus normal tissue (log2 FC = +0.630, t-test p < 0.001).
This table shows molecular features associated with PLA2G5 in patient tissues and cancer cell lines. In patient samples, PLA2G5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
